Internship Report: Analysis of Pharmaceutical Industry in Bangladesh & GlaxoSmithKline

UIU Institutional Repository

    • Login
    View Item 
    •   UIU DSpace Home
    • School of Business and Economics (SoBE)
    • Business Administration (BBA)
    • Internship Report (BBA)
    • General
    • View Item
    •   UIU DSpace Home
    • School of Business and Economics (SoBE)
    • Business Administration (BBA)
    • Internship Report (BBA)
    • General
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Internship Report: Analysis of Pharmaceutical Industry in Bangladesh & GlaxoSmithKline

    Thumbnail
    View/Open
    final-Intershhip-Report-Md-Fayez-Uddin-111141458.pdf (1.287Mb)
    Date
    2018-07
    Author
    Uddin, Md Fayez
    Metadata
    Show full item record
    Abstract
    The national pharmaceutical market in Bangladesh has been increasing in recent years and currently the market stands at 142 billion BDT. Demand for good quality drugs is on the rise and the local market is expected to reach BD 160 billion by 2018. Bangladesh pharmaceutical companies supply generic products and can charge premiums for their products. The top 10 companies have about 67% of the market. It is very complicated to enter this sector due to a high investment. GlaxoSmithKline Bangladesh Ltd is listed on the Dhaka Stock Exchange and has been fairly successful in the stock market. GlaxoSmithKline Bangladesh Limited has a very high dividend payment rate that primarily attracts the company's shareholders. The profitability of this company declined in 2016. The company has a very low current ratio that could pose a threat to it. Therefore, the company should focus more on this problem and should be careful to monitor the debts. Although, after comparing the financial report of GSK with that of Beximco Pharmaceutical and Reckitt Benckiser, it was found that GSK had a good financial performance It should work on expanding their product line, as it has a narrow product line and should also improve their current relationship. Shareholders would benefit greatly if the company could increase its earnings per share ratio. To improve performance, GSK should focus more on expanding the product line and payment rate.
    URI
    http://dspace.uiu.ac.bd/handle/52243/360
    Collections
    • General [1404]

    Copyright 2003-2017 United International University
    Contact Us | Send Feedback
    Developed by UIU CITS
     

     

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Copyright 2003-2017 United International University
    Contact Us | Send Feedback
    Developed by UIU CITS